SWISS BIOTECH SUCCESS STORY





- Family-run pharmaceutical group founded in 1976 in Ticino with global focus
 - Over 700 employees in Switzerland, USA, Ireland, Monaco and China
- Applies innovation to finding solutions to improve the lives of people with cancer, investing approximately 25% of its profits in R&D
- Development of new treatments to fulfill more medical needs, all guided and underpinned by core family values of quality, integrity and respect
 - Helsinn is certified as a sustainable company

 Investment Fund to invest in the future of healthcare and advance early-stage opportunities: providing funding and strategic support to innovative companies



THE LEADERSHIP TEAM



Riccardo Braglia
Helsinn Group Vice
Chairman & CEO



Giorgio Calderari Helsinn Group General Manager & COO



KNOWLEDGE

- Global presence with deep expertise in R&D with 20 clinical trials (2016–2018)
- World-class API and Drug Product facilities in Switzerland and Ireland
- Growing presence in the US, with an integrated specialty company with direct sales
- Commercial activities started in China in 2019



MARKETED PRODUCTS

- In the field of Mycosis fungoides-type T cell lymphoma
- Targeting Chemotherapy-Induced Nausea and Vomiting (CINV)



PIPELINE

- Focus on cancer therapeutics and cancer supportive care
- Phase III studies for lead therapeutic pipeline assets, targeting acute myeloid leukaemia (AML) and cancer cachexia and anorexia
- Broad portfolio of early phase projects



PARTNERSHIPS

- Strong alliances with worldwide partners and service providers who share company mission and vision
- Global network of over 80 commercial partnerships across 190 countries





- **★** Completed achievement with lasting impact
- **★** Strong impact on society
- **★** Product approval and sustainable revenues
- **★** Important IP, innovative deal-making, acquisition
- Involvement of one or more Swiss citizens
- **★** Swiss-based company/institution
- **Creation of jobs in Switzerland**

Organized by



